
Elevate Medical Affairs Podcast Channel
Podcast channel for the Medical Affairs Professional Society (MAPS). Global excellence in Medical Affairs from today's leaders.
Latest episodes

Oct 9, 2020 • 26min
Expert Engagement: Driving the Strategic Impact of Medical Affairs
External experts play a key role in the success or failure of the innovations delivered by the pharma/biotech industry. In today’s environment, restrictions continue to impede broad access to practicing physicians who in turn have less autonomy and it’s harder to gain access to them. At the same time, the complexity of the science behind future products increases the needs for diverse involvement aligned experts. Strategic engagement provides insights as new product develop, generate data, refine strategy and create relevant, credible and persuasive scientific communication. Thus relationships built and fostered through Medical Affairs are becoming more valuable in creating awareness and adoption. This podcast will explore how successful expert relationships reflect trust and needs in long-term cooperation from both parties.

Oct 6, 2020 • 12min
Medical Affairs Plans: from Strategic Planning to Measuring Impact - episode 1
The Series Podcast Objectives are: Understand how the medical affairs strategic planning process can drive decision making throughout the year Gain insight into the value medical affairs bring across an organization when an effective, collaborative, aligned medical strategy plan is developed Obtain a working knowledge of how cross-functional teams within medical affairs can reference strategic plans to inform decision making and assess impact of efforts Monica DeAbadal, MD, MBA/HSA, Vice President, Medical Excellence at Ipsen and MAPS Medical Strategy & Launch Excellence co-lead, culled out highlights from the Medical Strategy Strategy Planning live session at the March 2020 Annual MAPS Conference.The session speakers who provided these critical intellectual components of Building the Medical Affairs Strategic Plan are: Peter Piliero, MD, Vice President & Head, Medical Affairs Americas at GSK Consumer Healthcare; Eileen K Sawyer, PhD, Vice-President, Global Medical Affairs, UniQure; and, Anna Walz, CEO of MedEvoke.

Sep 11, 2020 • 16min
Executive Leadership Perspectives on MA Strategic Planning - episode 2
In this second of two podcasts, Pete Piliero, MD, VP & Head, Medical Affairs Americas, GSK Consumer Healthcare, moderates a discussion on Global/Regional/Local Planning; Approach to MA Strategic Planning - Rare Disease & Oncology; and, Compliance Considerations.Panelists are: Tina Beaman, VP and Chief Compliance Officer, Karyopharm Therapeutics Ed Gudaitis, President & CEO Acerus Pharma Keith Johns, VP, Global Marketing and Alliance Management, Eli Lilly & Co Maria Rivas, Chief Medical Officer, EMD Serono/Merck KGaA

Sep 11, 2020 • 12min
Executive Leadership Perspectives on Medical Affairs Strategic Planning - Episode 1
In this first of two podcasts, Pete Piliero, MD, VP & Head, Medical Affairs Americas, GSK Consumer Healthcare, moderates a discussion on Contributions Medical Affairs Makes to Asset Strategic Plans; and Time Horizon, Refreshing, and Resourcing of a Medical Affairs Plan. Panelists are: Ed Gudaitis, MBA, President & CEO Acerus Pharma Keith Johns, MBA, VP, Global Marketing and Alliance Management, Eli Lilly & Co; Maria Rivas, MD, Chief Medical Officer, EMD Serono/Merck KGaA

Aug 28, 2020 • 15min
The application of Real World Evidence in Regulatory Decision Making
Cerise James, MD, moderates this podcast presentation by the MAPS Evidence Generation Focus Area Working Group in which Neil Belson, JD, discusses Real World Evidence and its impact. The podcast objectives are: To define Real World Evidence, and to demonstrate RWE and its impact to Biotech/Pharma.Mr. Belson will address a variety of topics including: The significance of Real World Evidence for the pharmaceutical and medical device industry; and, how the FDA views Real World Evidence. This is the first podcast in a series.

May 22, 2020 • 45min
European Union Medical Device Regulations (EUMDR): ep 2
In this second podcast on the EUMDR, panelists John Pracyk, MD, PhD, MBA, Worldwide Integrated Leader, Medical Affairs, Pre-Clinical & Clinical Research, DePuy Synthes - Spine | Johnson & Johnson Medical Devices Companies welcomes Philip Desjardins, JD, Vice President, Global Regulatory Affairs Spine and Medical Device Regulatory Policy, DePuy Synthes | Johnson & Johnson Medical Devices Companies, and Drilon Saliu, PharmD, MBA, Head, Medical, Clinical and HEOR, Connected Care, Philips, continue their comprehensive discussion of: Covid’s impact on EUMDR; USFDA and EUMDR global regulator comparison; short and long term impacts; how Brexit might impact the UK’s regulatory oversight; the importance of investing in top talent; new capabilities that are required; the importance of leading with influence; and, evidentiary compliance planning and budget impact.

Apr 7, 2020 • 21min
European Union Medical Device Regulations (EUMDR): ep 1 Podcast Objectives, Panel Introductions, Why EUMDR?, and What does it really mean?
Host John Pracyk, MD, PhD, MBA, Worldwide Integrated Leader, Medical Affairs, Pre-Clinical & Clinical Research, DePuy Synthes - Spine | Johnson & Johnson Medical Devices Companies welcomes Philip Desjardins, JD, Vice President, Global Regulatory Affairs Spine and Medical Device Regulatory Policy, DePuy Synthes | Johnson & Johnson Medical Devices Companies, and Drilon Saliu, PharmD, MBA, Head, Medical, Clinical and HEOR, Connected Care, Philips, to share insights into the importance of compliance with the new European Device Medical Regulation (EUMDR), including key deadlines for compliance.

Feb 27, 2020 • 18min
Transitioning between Pharma and MedTech…and vice versa: ep 2 Transferable skills…What challenges exist?
If you’re considering a career transition, asking: “What’s in it for me?” is just as important as “What’s in it for the company?” During this podcast, Dr. Rubinstein asks the panelists, Dr. Sean Lilienfeld and Huub Kreuwel, why they considered making the change from one area to another. The potential for expanding your skillsets is an important consideration but it is not the only one.

Feb 27, 2020 • 14min
Transitioning between Pharma and MedTech…and vice versa: ep 3 Customer Preferences, Patient Centricity and Payer Interactions
While there are similarities in decision making between Pharma and MedTech, it can be difficult to get face time with physicians but is still relatively easy to get face time with surgeons particularly when the medical technology is more complex. Asking what success looks like to the patient is a critical element in a successful career transition.

Feb 27, 2020 • 17min
Transitioning between Pharma and MedTech…and vice versa: ep 6 Strategies for Transitioning
What does it take to go from an external deep subject matter expert to an internal medical expert? Specializing in one area may limit your ability to transition from one therapeutic area to another; making this adjustment requires the ability to take a risk, the skills to gain trust, and comfort with admitting the limitations of your skill sets.